Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.

Malinge S, Bliss-Moreau M, Kirsammer G, Diebold L, Chlon T, Gurbuxani S, Crispino JD.

J Clin Invest. 2012 Mar;122(3):948-62. doi: 10.1172/JCI60455. Epub 2012 Feb 22.

2.

DYRK1A in Down syndrome: an oncogene or tumor suppressor?

Birger Y, Izraeli S.

J Clin Invest. 2012 Mar;122(3):807-10. doi: 10.1172/JCI62372. Epub 2012 Feb 22.

3.

Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.

Greene ME, Mundschau G, Wechsler J, McDevitt M, Gamis A, Karp J, Gurbuxani S, Arceci R, Crispino JD.

Blood Cells Mol Dis. 2003 Nov-Dec;31(3):351-6.

PMID:
14636651
4.

Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.

Rainis L, Bercovich D, Strehl S, Teigler-Schlegel A, Stark B, Trka J, Amariglio N, Biondi A, Muler I, Rechavi G, Kempski H, Haas OA, Izraeli S.

Blood. 2003 Aug 1;102(3):981-6. Epub 2003 Mar 20.

5.

Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.

Roy A, Roberts I, Norton A, Vyas P.

Br J Haematol. 2009 Oct;147(1):3-12. doi: 10.1111/j.1365-2141.2009.07789.x. Epub 2009 Jul 6. Review.

PMID:
19594743
6.

miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia.

Klusmann JH, Li Z, Böhmer K, Maroz A, Koch ML, Emmrich S, Godinho FJ, Orkin SH, Reinhardt D.

Genes Dev. 2010 Mar 1;24(5):478-90. doi: 10.1101/gad.1856210.

7.

Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome.

Alford KA, Slender A, Vanes L, Li Z, Fisher EM, Nizetic D, Orkin SH, Roberts I, Tybulewicz VL.

Blood. 2010 Apr 8;115(14):2928-37. doi: 10.1182/blood-2009-06-227629. Epub 2010 Feb 12.

8.

A novel mutation in the GATA1 gene associated with acute megakaryoblastic leukemia in a Korean Down syndrome patient.

Kim IS, Park ES, Lim JY, Ki CS, Chi HS.

J Korean Med Sci. 2008 Dec;23(6):1105-8. doi: 10.3346/jkms.2008.23.6.1105. Epub 2008 Dec 24.

9.

Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.

Cushing T, Clericuzio CL, Wilson CS, Taub JW, Ge Y, Reichard KK, Winter SS.

J Pediatr. 2006 May;148(5):687-9.

PMID:
16737888
10.

A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.

Haemmerling S, Behnisch W, Doerks T, Korbel JO, Bork P, Moog U, Hentze S, Grasshoff U, Bonin M, Rieß O, Janssen JW, Jauch A, Bartram CR, Reinhardt D, Koch KA, Bandapalli OR, Kulozik AE.

Br J Haematol. 2012 Apr;157(2):180-7. doi: 10.1111/j.1365-2141.2012.09028.x. Epub 2012 Feb 1.

PMID:
22296450
11.

Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling.

Bourquin JP, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P, Baruchel A, Cavé H, Dastugue N, Hasle H, Kaspers GL, Lessard M, Michaux L, Vyas P, van Wering E, Zwaan CM, Golub TR, Orkin SH.

Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3339-44. Epub 2006 Feb 21.

12.

GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.

Pine SR, Guo Q, Yin C, Jayabose S, Levendoglu-Tugal O, Ozkaynak MF, Sandoval C.

Leuk Res. 2005 Nov;29(11):1353-6.

PMID:
15916804
13.
14.

Natural history of GATA1 mutations in Down syndrome.

Ahmed M, Sternberg A, Hall G, Thomas A, Smith O, O'Marcaigh A, Wynn R, Stevens R, Addison M, King D, Stewart B, Gibson B, Roberts I, Vyas P.

Blood. 2004 Apr 1;103(7):2480-9. Epub 2003 Dec 4.

15.

Chromosome 7 abnormalities in acute megakaryoblastic leukemia associated with Down syndrome.

Kobayashi K, Usami I, Kubota M, Nishio T, Kakazu N.

Cancer Genet Cytogenet. 2005 Apr 15;158(2):184-7. Review.

PMID:
15796967
16.

Transient myeloproliferative disorder with partial trisomy 21.

Takahashi T, Inoue A, Yoshimoto J, Kanamitsu K, Taki T, Imada M, Yamada M, Ninomiya S, Toki T, Terui K, Ito E, Shimada A.

Pediatr Blood Cancer. 2015 Nov;62(11):2021-4. doi: 10.1002/pbc.25624. Epub 2015 Jul 1.

PMID:
26138905
17.

Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.

Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, Crispino JD.

Nat Genet. 2002 Sep;32(1):148-52. Epub 2002 Aug 12.

PMID:
12172547
18.

Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome.

Pine SR, Guo Q, Yin C, Jayabose S, Druschel CM, Sandoval C.

Blood. 2007 Sep 15;110(6):2128-31. Epub 2007 Jun 18.

19.

Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.

Ono R, Hasegawa D, Hirabayashi S, Kamiya T, Yoshida K, Yonekawa S, Ogawa C, Hosoya R, Toki T, Terui K, Ito E, Manabe A.

Eur J Pediatr. 2015 Apr;174(4):525-31. doi: 10.1007/s00431-014-2430-3. Epub 2014 Sep 30. Review.

PMID:
25266042
20.

Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome.

Nikolaev SI, Santoni F, Vannier A, Falconnet E, Giarin E, Basso G, Hoischen A, Veltman JA, Groet J, Nizetic D, Antonarakis SE.

Blood. 2013 Jul 25;122(4):554-61. doi: 10.1182/blood-2013-03-491936. Epub 2013 Jun 3.

Supplemental Content

Support Center